Most medicine is timed by the wall clock: once daily, twice daily, take with breakfast. That convention exists because it is easy to follow, not because it matches human biology. A startup called TimeTeller is betting on the mismatch — putting the body's internal clock at the centre of personalised medicine, TechCrunch reports.
The science underneath is legitimate and unglamorous. Circadian rhythms govern blood pressure, hormone release, metabolism and cell division, which means a drug's effect can vary depending on when the body encounters it. There is real clinical evidence that timing matters for some treatments: certain blood-pressure medications, statins, and cytotoxic chemotherapy have all shown time-of-day effects in studies. What has been missing is not the observation but a practical way to act on it in the clinic — because the clock that matters is the patient's internal phase, not the one on the wall. A night-shift worker whose biological morning falls at midnight is being dosed at the wrong biological time by any fixed schedule.
The gap TimeTeller is trying to close is measurement: establishing where a given patient's circadian clock stands, so that treatment can be scheduled to that phase rather than to a hospital convenience. Framed that way, the company is less a drug developer than an infrastructure play — the assay, and the clinical evidence that acting on it changes outcomes.
That second part is the hard part, and it is where the field has repeatedly stumbled. Circadian medicine has produced encouraging results in narrow settings while large, general 'chronotherapy' trials have been mixed, and the failure mode is familiar: a biomarker that correlates with a disease does not automatically become a decision rule that improves it. Regulators will want endpoint data — did timing therapy actually reduce events, not merely shift a marker — and payers will want to know whether the diagnostic changes care enough to be ordered.
The realistic near-term wins are probably narrow and specific: oncology dosing, transplant and vaccination timing, and shift-work populations whose biology is systematically misaligned with every standard protocol. The broader question TimeTeller raises is not whether our clocks are personal — they plainly are — but whether medicine is ready for dosage decisions that depend on them.
For patients, the practical takeaway is modest but real. 'Take at the same time each day' is already good advice; it may turn out to be the crude first version of something more precise.
